- active not recruitingPHASE2, PHASE3
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
This study is testing a new medicine, linsitinib, for people with active, moderate to severe Thyroid Eye Disease (TED). Researchers want to see if it's safe and effective compared to a dummy pill over 24 weeks.
United States · Canada · Italy - active not recruiting
Rate of Progression in EYS Related Retinal Degeneration
This study aims to understand how an eye condition called EYS-related retinitis pigmentosa progresses over time. Researchers want to learn more about how it affects vision to help develop treatments in the future. It involves monitoring people with EYS gene mutations for four years.
United States · Canada · Finland - recruitingPHASE3
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
This study looks at a serious eye condition called submacular haemorrhage (bleeding under the macula) caused by wet AMD. It compares standard eye injections with a combination of injections and surgery to see if surgery can improve vision more for this specific type of bleeding.
Germany · Ireland · Poland - recruitingPHASE3
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
This study is testing a new medicine called sepofarsen for a rare eye condition called Leber Congenital Amaurosis Type 10 (LCA10). It aims to see if sepofarsen can improve vision safely in people with this condition.
United States · Belgium · Brazil - active not recruiting
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
This study looks at how a serious eye condition called Geographic Atrophy (GA) develops over time. GA is a type of 'dry' Age-related Macular Degeneration (AMD). Researchers are checking for 'biomarkers' in blood and how they relate to changes in the eye.
United States · United Kingdom - active not recruitingPHASE2, PHASE3
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
This study looks at a new treatment called sepofarsen for a rare eye condition called Leber Congenital Amaurosis 10 (LCA10), which causes blindness. We want to see if it helps improve sight, how safe it is, and how well people tolerate it.
United States · Belgium · Brazil